Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640854 | 0.84 | KCNH2 (0.36) | CCR5OPRD1KCNH2SIGMAR1MCHR2 | |
| SCHEMBL13640901 | 0.83 | OPRD1 (0.35) | CCR5OPRD1KCNH2MCHR2 | |
| SCHEMBL13640896 | 0.81 | MCHR2 (0.38) | CCR5KCNH2SIGMAR1CYP2D6MCHR2 | |
| SCHEMBL13640967 | 0.81 | SIGMAR1 (0.35) | OPRD1KCNH2SIGMAR1 | |
| SCHEMBL14467633 | 0.80 | KDM1A (0.38) | CCR5SIGMAR1 | |
| SCHEMBL12899386 | 0.76 | SIGMAR1 (0.39) | CCR5KCNH2SIGMAR1 | |
| SCHEMBL12084586 | 0.75 | OPRM1 (0.39) | CCR5KCNH2SIGMAR1CYP3A4PER2 | |
| SCHEMBL12929082 | 0.75 | OPRM1 (0.39) | CCR5KCNH2SIGMAR1CYP3A4PER2 | |
| SCHEMBL15339917 | 0.75 | OPRM1 (0.39) | CCR5KCNH2SIGMAR1CYP3A4PER2 | |
| SCHEMBL13640732 | 0.74 | MCHR2 (0.45) | KCNH2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CCR5 293/4885OPRD1 221/4885KCNH2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.